151 related articles for article (PubMed ID: 35853885)
1. Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2.
Wu S; Qi L; Chen H; Zhang K; He J; Guo X; Shen L; Zhou Y; Zhong X; Zheng S; Zhou J; Chen Y
NPJ Breast Cancer; 2022 Jul; 8(1):86. PubMed ID: 35853885
[TBL] [Abstract][Full Text] [Related]
2. The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response.
Zhang Y; Park JY; Zhang F; Olson SH; Orlow I; Li Y; Kurtz RC; Ladanyi M; Chen J; Toland AE; Zhang L; Andreassen PR
Hum Mutat; 2021 Feb; 42(2):150-163. PubMed ID: 33169439
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of 84 PALB2 variants of uncertain significance.
Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
[TBL] [Abstract][Full Text] [Related]
4. Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction.
Caleca L; Catucci I; Figlioli G; De Cecco L; Pesaran T; Ward M; Volorio S; Falanga A; Marchetti M; Iascone M; Tondini C; Zambelli A; Azzollini J; Manoukian S; Radice P; Peterlongo P
Front Oncol; 2018; 8():480. PubMed ID: 30410870
[TBL] [Abstract][Full Text] [Related]
5. Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer.
Toh MR; Low CE; Chong ST; Chan SH; Ishak NDB; Courtney E; Kolinjivadi AM; Rodrigue A; Masson JY; Ngeow J
Fam Cancer; 2020 Apr; 19(2):123-131. PubMed ID: 32048105
[TBL] [Abstract][Full Text] [Related]
6. PALB2 Variants: Protein Domains and Cancer Susceptibility.
Nepomuceno TC; Carvalho MA; Rodrigue A; Simard J; Masson JY; Monteiro ANA
Trends Cancer; 2021 Mar; 7(3):188-197. PubMed ID: 33139182
[TBL] [Abstract][Full Text] [Related]
7. A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.
Rodrigue A; Margaillan G; Torres Gomes T; Coulombe Y; Montalban G; da Costa E Silva Carvalho S; Milano L; Ducy M; De-Gregoriis G; Dellaire G; Araújo da Silva W; Monteiro AN; Carvalho MA; Simard J; Masson JY
Nucleic Acids Res; 2019 Nov; 47(20):10662-10677. PubMed ID: 31586400
[TBL] [Abstract][Full Text] [Related]
8. Functional Characterization of
Boonen RACM; Vreeswijk MPG; van Attikum H
Front Mol Biosci; 2020; 7():169. PubMed ID: 33195396
[TBL] [Abstract][Full Text] [Related]
9. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2.
Boonen RACM; Rodrigue A; Stoepker C; Wiegant WW; Vroling B; Sharma M; Rother MB; Celosse N; Vreeswijk MPG; Couch F; Simard J; Devilee P; Masson JY; van Attikum H
Nat Commun; 2019 Nov; 10(1):5296. PubMed ID: 31757951
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers.
Janssen B; Bellis S; Koller T; Tischkowitz M; Liau SS
J Hum Genet; 2020 Jan; 65(2):199-205. PubMed ID: 31619740
[TBL] [Abstract][Full Text] [Related]
13. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
Zhang F; Fan Q; Ren K; Andreassen PR
Mol Cancer Res; 2009 Jul; 7(7):1110-8. PubMed ID: 19584259
[TBL] [Abstract][Full Text] [Related]
14. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
15. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
17. Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Park D; Bergin SM; Jones D; Ru P; Koivisto CS; Jeon YJ; Sizemore GM; Kladney RD; Hadjis A; Shakya R; Ludwig T
Cancer Res; 2020 Oct; 80(19):4172-4184. PubMed ID: 32732220
[TBL] [Abstract][Full Text] [Related]
18. PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Sy SM; Huen MS; Chen J
Proc Natl Acad Sci U S A; 2009 Apr; 106(17):7155-60. PubMed ID: 19369211
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and Spectrum of Germline
Fanale D; Fiorino A; Incorvaia L; Dimino A; Filorizzo C; Bono M; Cancelliere D; Calò V; Brando C; Corsini LR; Sciacchitano R; Magrin L; Pivetti A; Pedone E; Madonia G; Cucinella A; Badalamenti G; Russo A; Bazan V
Front Oncol; 2021; 11():682445. PubMed ID: 34178674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
